Since outpatient guideline-based psychotherapy according to § 26 of the Psychotherapy Guidelines is generally indicated for all mental disorders (potentially at different time points in the course of treatment), the disorder-specific indication essentially refers to the entire range from "F00 to F99." In each individual case, it is up to the psychotherapist to decide whether outpatient guideline-based therapy is indicated for the diagnosed disorders. Considering studies on the distribution of di
Conditions
Interventions
Group 1: Intervention group 1: QUATEMAR-standard - app (available during the entire observation period) + 6 telephone coachings (1x/week à 25min in 6 weeks)
The app contains a search function for reg
Sponsors
Lehrstuhl für Klinische Psychologie und Psychotherapie, Friedrich-Alexander-Universität Erlangen-Nürnberg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria: Adults for whom (a) a licensed psychotherapist has indicated the need for outpatient guideline-based psychotherapy during a psychotherapeutic consultation and suggested the QUATEMAR program to bridge the waiting time, (b) there is a risk that such treatment might not start in a timely manner (i.e., more than 4 weeks wait time), (c) have a valid email address, (d) access to an app-enabled device (Android operating system version =7 with installed Google Play Store or iOS version =15) is ensured, and (e) whose health insurance participates in the QUATEMAR program.
Exclusion criteria
Exclusion criteria: Exclusion criteria: (d) Acute risk of self-harm or (e) harm to others, (f) acute psychotic symptoms, insurmountable (g) language or (h) neurocognitive barriers, as well as (k) currently undergoing psychotherapeutic treatment or (l) psychotherapy is imminent (< 4 weeks).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Psychopathological symptom burden assessed using the AMDP system (Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie) via interview at baseline as well as 12 and 24 weeks after randomization; the assessment 24 weeks after randomization constitutes the primary endpoint, while the assessment 12 weeks after randomization is exploratory | — |
Secondary
| Measure | Time frame |
|---|---|
| Waiting time for beginning psychotherapy assessed using self-report and routine data from participating health insurance companies at baseline as well as 12 and 24 weeks after randomization Psychopathological symptom burden assessed using the Mini-Symptom-Checklist (Mini-SCL) at baseline as well as 12 and 24 weeks after randomization Psychosocial functioning level assessed using the Social Functioning Questionnaire (SFQ) at baseline as well as 12 and 24 weeks after randomization Quality of life assessed using the Short-Form Health Survey (SF-12 in self-rating) at baseline as well as 12 and 24 weeks after randomization Healthcare costs assessed using the Client Sociodemographic and Service Receipt Inventory (CSSRI) and routine data from participating health insurance companies at baseline as well as 12 and 24 weeks after randomization Severity of depressive disorder assessed using the Hamilton rating scale for depression (HAM-D) at baseline as well as 12 and 24 weeks after randomization Severity of anxiety disorder assessed using the Hamilton Anxiety Rating Scale (HAM-A) at baseline as well as 12 and 24 weeks after randomization The hypotheses to be tested relate to changes between randomization (T1, baseline) and the effect measurement conducted 24 weeks after randomization (T3). To capture mid-term effects, an additional exploratory analysis of the changes between T1 and an interim measurement 12 weeks after randomization (T2) will also be conducted. The following additional tertiary outcomes will be assessed: For the tertiary research hypotheses, the following contextual variables will be collected, and their impact on effectiveness will be examined: health care service density, income, educational level, migration background, social assertiveness (with Rathus Assertiveness Schedule, RAS) Problem-solving skills assessed using the Self-Efficacy Scale - Short Form (ASKU) at baseline as well as 12 and 24 weeks after randomization Emotion regulat | — |
Countries
Germany
Contacts
Public ContactJennifer Kulke
Lehrstuhl für Klinische Psychologie und Psychotherapie, Friedrich-Alexander-Universität Erlangen-Nürnberg
Outcome results
None listed